Subscribe to
our newsletters

Subscribe to our newsletters!

Subscribe to our newsletter and get the latest news from the Nordics straight to your inbox.

Search in Nordic Life Science Insight

-
April 24, 2020

Tumorad® patent approval in Japan

Tumorad® patent approval in Japan

-
-
April 24, 2020

Spago Nanomedical has received notice of allowance for the company´s patent application including Tumorad® product protection in Japan.

”The patent covers the nanomaterial that is central for the Tumorad®-project. As Japan represent a potentially large market for radionuclide therapies, this approval is important. It also underscores the quality of our innovation and strengthens the commercial prospects of the project”, says Spago Nanomedical CEO Mats Hansen.

The patent, titled ”Nanostructures and applications thereof” (application no. 2017-501494), is valid until 2035.

With the approval Spago Nanomedical holds product protection for Tumorad® in the largest markets for radionuclide therapy. Patent protection has previously been granted in several strategically important regions, including the USA and EU.

Tumorad® is a new type of radionuclide therapy based on Spago Nanomedical´s proprietary material and a therapeutically relevant radioisotope for tumor selective radiation therapy of cancer.

Access to new therapies is essential for effective treatment of many forms of cancer. Tumorad® holds potential for treatment of aggressive and metastatic tumors, as monotherpay or in synergy with other treatment types. Currently an extensive program for documentation of proof of concept is ongoing in preparation for preclinical safety studies and clinical trials.

PDF: Tumorad® patent approval in Japan

Last updated:
April 24, 2020

Click here to read more about us!
Get in touch with us!
Visit us
Send us mail
Other articles published by
No items found.

Spago Nanomedical has received notice of allowance for the company´s patent application including Tumorad® product protection in Japan.

”The patent covers the nanomaterial that is central for the Tumorad®-project. As Japan represent a potentially large market for radionuclide therapies, this approval is important. It also underscores the quality of our innovation and strengthens the commercial prospects of the project”, says Spago Nanomedical CEO Mats Hansen.

The patent, titled ”Nanostructures and applications thereof” (application no. 2017-501494), is valid until 2035.

With the approval Spago Nanomedical holds product protection for Tumorad® in the largest markets for radionuclide therapy. Patent protection has previously been granted in several strategically important regions, including the USA and EU.

Tumorad® is a new type of radionuclide therapy based on Spago Nanomedical´s proprietary material and a therapeutically relevant radioisotope for tumor selective radiation therapy of cancer.

Access to new therapies is essential for effective treatment of many forms of cancer. Tumorad® holds potential for treatment of aggressive and metastatic tumors, as monotherpay or in synergy with other treatment types. Currently an extensive program for documentation of proof of concept is ongoing in preparation for preclinical safety studies and clinical trials.

PDF: Tumorad® patent approval in Japan

Last updated:
April 24, 2020

Click here to read more about us!
Get in touch with us!
Visit us
Send us mail
Other articles published by
No items found.